Delivering tomorrow's treatments for today's patients

The Leigh Syndrome International Consortium is a patient-driven research network that will establish global best practices of care for Leigh syndrome patients.

In an effort to move fast toward treatments and potential therapies, five of the world’s leading mitochondrial disease patient advocacy groups have joined together to form and fund the Leigh Syndrome International Consortium. Two US based organisations, the United Mitochondrial Disease Foundation (UMDF) and People Against Leigh Syndrome (PALS), along with Australian based Mito Foundation, Mitocon ODV of Italy and the Lily Foundation from the UK have collectively pledged $1 million USD to support this innovative, multi-year project to fund research with a focus on improving diagnosis, therapeutic development and optimized patient care for Leigh syndrome patients.